Grantvello Find funders

Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)

Upcoming

National Institutes of Health · Opportunity number PAR-27-009 · Forecast

Expected postingNov 25, 2026
Closing dateJan 25, 2027
Award ceilingNot listed
Expected awardsNot listed
From Grants.gov

Eligibility

Nonprofits are listed as eligible applicants.

  • Public housing authorities/Indian housing authorities
  • County governments
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Special district governments
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Public and state controlled institutions of higher education
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Small businesses
  • Private institutions of higher education
  • State governments
  • Independent school districts
  • For profit organizations other than small businesses
  • Native American tribal governments (Federally recognized)
  • City or township governments
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Description

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to continue to support the Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium, which coordinates research on prevention, diagnosis, treatment, and mechanisms of resistance in SCLC. The CC manages administrative activities, centralized databases, tissue banking and a virtual biospecimen resource, biostatistics and bioinformatics support, in vivo and in vitro model repositories, and communications and website operations for the Consortium. Since its establishment in response to the Recalcitrant Cancer Research Act, the Consortium has catalyzed SCLC-focused research and enabled major advances in molecular characterization, tumor heterogeneity, microenvironment and immune evasion, biomarker development, preclinical models, therapeutic strategies, and clinical translation. The current U24 CC, based at Sloan Kettering with collaborating institutions, organizes meetings, maintains extensive -omics and model resources, supports young investigators, and provides datasets and models to the research community. The reissue NOFO will support a five-year cooperative agreement to sustain these shared resources and collaborations. This is a Forecast for a single source that will invite application(s) from eligible organization(s) to apply. Please see the Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

Funding

Total program fundingNot listed
Award floorNot listed
Award ceilingNot listed
CategoryHealth
Assistance listing93.393, 93.394, 93.395, 93.396

Official sources

Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.